NGL Fine-Chem Limited (NSE:NGLFINE)

Checkpoint Therapeutics Revenue

NGL Fine-Chem had revenue of 1.04B INR in the quarter ending June 30, 2025, with 14.80% growth. This brings the company's revenue in the last twelve months to 3.82B, up 6.50% year-over-year. In the fiscal year ending March 31, 2025, NGL Fine-Chem had annual revenue of 3.68B with 8.73% growth.

• Revenue (ttm): 3.82B
• Revenue Growth: +6.50%
• P/S Ratio: 1.99
• Revenue / Employee: 7.34M
• Employees: 520
• Market Cap: 7.59B

Revenue History

Fiscal Year End	Revenue	Change	Growth
Mar 31, 2025	3.68B	295.68M	8.73%
Mar 31, 2024	3.39B	606.08M	21.79%
Mar 31, 2023	2.78B	-394.22M	-12.42%
Mar 31, 2022	3.18B	595.28M	23.08%
Mar 31, 2021	2.58B	1.06B	70.07%